Pfizer and Genentech Duke it Out in Court over Herceptin Biosimilar Patents Post author:Sam Post published:November 21, 2017 Post category:BioPharma Genentech is claiming that Pfizer’s proposed biosimilar infringes 40 of its patents. Source: BioSpace You Might Also Like Biotech Guru's Roivant Sciences Could Soon Double Its Headcount in North Carolina March 5, 2017 Ceapro Reports 2016 Financial Results And Provides Corporate Update April 5, 2017 Mass Layoffs Hit Ariad Employees After Takeda's $5.2 Billion Buyout Deal March 29, 2017
